HORGEN -
The first subject dosing marks the beginning of a combined single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a/1b clinical study, conducted in collaboration with Numab's
'It is an exciting milestone for Numab to initiate this study of NM26-2198, our first product candidate focused on the treatment of inflammatory conditions and our second multi-specific antibody therapeutic to advance to the clinic,' said
AD is an inflammatory skin condition which is characterized by a vicious cycle of skin inflammation that causes itching and scratching, which in turn exacerbates damage to the skin barrier and inflammation and furthers itching, resulting in the characteristic skin lesions for which AD is known. In
NM26-2198 is a first-in-class bi-specific antibody designed to simultaneously block itch and inflammation, with the aim of improving quality of life relative to current standard of care treatment. NM26-2198 inhibits three key pathways involved in disease pathogenesis of AD. While standard of care blocks IL-4 and IL-13, NM26-2198 blocks IL-31 in addition, thereby specifically targeting the neuroinflammatory pathway that causes itch.
'Based on its unique mechanism of action, we believe that NM26-2198 has the potential to deliver faster and more pronounced relief from itch than the current standard of care AD treatment,' said
About NM26-2198
NM26-2198 is a bi-specific antibody which targets IL-4R (type I and type II receptors) and IL-31 for the treatment of atopic dermatitis (AD). The antibody therapeutic is designed to prevent IL-4/IL-13 and IL-31-induced keratinocyte immunopathology, immune cell activation, skin barrier function impairment and pruritis, all of which are hallmarks of the pathophysiology of atopic dermatitis. We believe that adding IL-31 mediated blockade of neuroinflammation to the repression of Th2 driven inflammation by IL-4/IL-13 blockade could enable a faster onset of action and improved efficacy compared to the current standard of care in AD, together with convenient subcutaneous administration. Numab is developing this molecule together with its Japanese partner
About Numab Therapeutics
Numab Therapeutics is an immunology and oncology-focused biopharmaceutical company based in
About
Kaken is an R&D driven pharmaceutical company, established in 1948, and its corporate philosophy is to help improve the quality of life of patients by serving as many people as possible to return smiles of happiness to their faces, through supplying superior pharmaceuticals. Recently, Kaken has increased its presence in dermatology and orthopedics, and Clenafin, a drug discovered in-house and first topical onychomycosis treatment in
Contact:
Tel: +1 781-235-3060
Email: numab@macdougall.bio
(C) 2023 Electronic News Publishing, source